Provides outpatient insurance coverage for non-pharmacological treatments and non-opioid drugs for chronic pain.
This bill would require most New York health insurance policies and contracts that cover pain treatment to include outpatient coverage for at least three non-pharmacological treatments for chronic pain and at least two FDA-approved non-opioid drugs for acute or chronic pain. The required non-pharmacological options must include at least one restorative treatment, one behavioral treatment, and one complementary treatment, with examples such as massage therapy, cognitive behavioral therapy, and acupuncture. Coverage for these services must be comparable to coverage for other covered benefits and for services provided by licensed professionals.
The bill also prohibits insurers from imposing financial requirements or treatment limits on non-opioid pain treatment that are more restrictive than those applied to substantially all medical benefits or to opioid-based pain treatment. It further bars insurers from disadvantaging non-opioid drugs relative to opioid or narcotic drugs through preferred-drug designations, prior authorization, step therapy, or similarly restrictive utilization controls. The bill defines key terms such as chronic pain, acute pain, financial requirement, and treatment limitation, and it applies to individual, group, blanket, and certain nonprofit health plans issued or renewed on or after the effective date.
The bill amends multiple sections of the New York Insurance Law, including sections 3216, 3221, and 4303, to create a uniform outpatient coverage mandate for pain treatment across individual, group, blanket, and certain corporation-issued health plans. It would expand required insurance benefits and limit insurers’ ability to use cost-sharing, prior authorization, step therapy, network restrictions, or formulary placement to make non-opioid pain treatments less accessible than opioid alternatives. The act would take effect on January 1 following enactment and apply to policies and contracts issued, renewed, modified, altered, or amended on or after that date.
The available voting history suggests strong support for the bill in committee, with the Senate Insurance Committee approving it 11-0 on May 5, 2025. No committee transcript excerpts were provided, so there is no recorded floor or committee debate to indicate broader opposition or support beyond the unanimous committee vote. Overall, the bill appears to have been received favorably as a patient-access and opioid-alternative measure.
The main policy issue embedded in the bill is how far insurers should be required to go in covering non-opioid and non-pharmacological pain treatments on terms equal to opioid-based care. Potential points of contention include the cost impact on insurers, the scope of mandated benefits, and whether the bill’s restrictions on prior authorization, step therapy, and formulary placement limit plan design flexibility. Supporters would likely emphasize improved access to safer pain-management options and reduced reliance on opioids, while critics may focus on premium effects and administrative constraints on utilization management.